PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · South Asian J Cancer 2025; 14(03): 439-444
DOI: 10.1055/s-0043-1774709
Original Article
Gynaecology - Cervical Section

Impact of Human Papillomavirus on Survival, Inflammation, and Immune Function in Patients with Cervical Cancer Undergoing Surgery

Autor*innen

  • Hui Hua

    1   Institute of Pharmacy and Pharmacology, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, University of South China, Hengyang, China.

  • Xiaoyong Lei

    1   Institute of Pharmacy and Pharmacology, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, University of South China, Hengyang, China.

  • Jia Yu

    1   Institute of Pharmacy and Pharmacology, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, University of South China, Hengyang, China.

  • Xinxin Zhang

    1   Institute of Pharmacy and Pharmacology, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, University of South China, Hengyang, China.
Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints

Abstract

No studies have examined the impact of human papillomavirus (HPV)-16 and HPV-18 on survival, inflammation biomarkers, and immune function in early-stage cervical cancer patients undergoing surgery. Patients diagnosed with early-stage cervical cancer were screened for high-risk HPV prior to surgery. The influence of HPV infection on survival, inflammatory markers, and immune function was investigated. Findings revealed that patients in the HPV-18 positive subgroup exhibited poorer disease-free survival (DFS) and elevated levels of interleukin-6 and C-reactive protein, along with decreased CD4+ T cells compared to patients who tested negative for HPV-18. Notably, early-stage cervical cancer patients with HPV-18 infection experienced worse DFS, heightened inflammatory markers, and compromised immune function.

Keywords

HPV-16 - HPV-18 - cervical cancer - survival - inflammation - immunity

Availability of Data and Material

Data are available from the corresponding author on reasonable request.


Ethics

The study was approved by the Ethics Committee of our hospital (No. 2018920121). All patients signed the written informed consent.




Publikationsverlauf

Artikel online veröffentlicht:
12. September 2023

© 2023. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India